FDA CBER Type C meeting will scrutinize statistical justification for pooled nonconcurrent published controls versus OST-400 ...
Hormone receptor and HER2 assessment remains the cornerstone for breast cancer subtyping and initial systemic therapy ...
Maureen Cox, PhD, and Jumana Abbadi, MD, explain how macrophage-derived BDNF drives sensory nerve growth into triple-negative ...
Patrick Borgen, MD, built Brooklyn's breast cancer program from 47 patients to 8,000. Now he and Joshua Feinberg, MD discuss ...
HR-positive disease accounts for approximately 70% to 80% of breast cancer diagnoses and carries a risk of recurrence that ...
The FDA granted accelerated approval to RP1 (vusolimogene oderparepvec; Tudriqev), an oncolytic virus therapy, in combination ...
Dr. Monty Pal concludes his discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by summarizing how he ...
Mark Agulnik, MD, discusses the trend away from surgery and toward targeted treatment of progressive desmoid tumors, and how ...
The FDA has cleared an investigational new drug (IND) application for Bria-PROS+, a personalized, off-the-shelf, whole-cell ...
Phase 3 SENOMAC randomized 2766 patients across five countries to completion ALND vs omission after up to two sentinel-node ...
Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges.
City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results